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ABSTRACT  
Objective: To investigate if buprenorphine/naloxone compared to methadone improves treatment 
retention and effectiveness among opioid dependent individuals. Design: Systematic literature review. 
Methods: Searches were conducted in PubMed and Scopus using the terms methadone, buprenorphine-
naloxone and opioid dependence. In PubMed the following filters were applied: humans, English, 
randomized controlled trials and meta-analysis. Studies that had opioid dependent subjects, treatments 
comparing buprenorphine-naloxone and methadone and outcomes measures of treatment retention and 
efficacy were included. Results: Otiashvili et al. found that daily observed doses of methadone and 
buprenorphine-naloxone were effective in reducing illicit buprenorphine and other illicit opioid use. 
Kamien et al. found that maintenance treatment with 16mg of buprenorphine-naloxone reduced opioid use 
at a rate equivalent to that achieved with 90mg of methadone. Hser et al. found that methadone appeared 
to be associated with better retention in treatment for opioid dependence than buprenorphine-naloxone, as 
does that use of higher doses of both medications. Buprenorphine-naloxone is associated with lower 
continued use of illicit opioids. Conclusion: Buprenorphine-naloxone may be more effective at 
preventing illicit opioid use than methadone, although this is inconsistent among the three studies. 
Retention rates are also inconclusive with only one study demonstrating higher retention rates with 
methadone treatment. With buprenorphine-naloxone demonstrating a better safety profile, fewer 
withdrawal effects, ease of use and less divergence, we recommend buprenorphine-naloxone over 
methadone as a first line treatment in opioid-dependent individuals.  
 
INTRODUCTION 
Opioids are a class of compounds that bind to mu-receptors in the central and peripheral nervous 
system eliciting an analgesic and euphoric effect. Opioid dependence has developed into a pervasive issue 
in North America, exacting an incredulous financial strain through costs associated with healthcare, 
mental illness, unemployment and crime. It is estimated that the cost of prescription opioid dependence in 
the U.S. alone amounts to nearly $55.1 billion dollars annually.1 The burden of opioid dependence in the 
United States is worsening, as the use of heroin and illicit use of prescription opioids are steadily 
increasing. As of 2014, it was estimated that 586,000 and 1.9 million Americans had a substance use 
disorder involving heroin and prescription pain relievers, respectively. With this expansion in opioid 
misuse, the unfortunate consequence of opioid overdose has also become prevalent. It was estimated that 
there were 10,574 deaths related to heroin overdose and 18,893 deaths related to prescription pain 
relievers in the U.S. in 2014.2 
Substance dependence, characterized by a compulsion to seek and take a drug, a loss of control in 
limiting intake and a negative emotional state when drug excess is withdrawn, is the result of complex 
and multifactorial processes involving genetic, epigenetic, cellular and molecular mechanisms.3 The 
behavior begins as a transition from occasional and controlled drug use to a loss in control and subsequent 
dependent behavior. Dependence manifests as several maladaptive behaviors which occur in stages: 
intoxication/binge, negative affect/withdrawal and preoccupation/anticipation that reinforce the addictive 
behavior. The intoxication/binge stage involves the acute, pleasurable stimuli associated with drug 
utilization. Opioids directly bind to receptors in the ventral tegmentum and nucleus accumbens resulting 
in dopamine release and euphoria, which ultimately reinforces drug use. Chronic drug exposure 
downregulates dopamine and other neurotransmitters involved in the neurocircuit associated with the 
acute reinforcing effects. Upon drug withdrawal, several mechanisms contribute to aversion and 
substance-seeking behavior. It is postulated that low dopamine levels cause anhedonia and amotivational 
symptoms, which consequently heighten the desire for the abused substance. The 
preoccupation/anticipation stage is characterized by an increased craving for the drug long after acute 
withdrawal. It is often triggered by stress, which activates brain circuits involved in reward processing 
and thus stimulates the compulsion for drug use. Both dopamine and glutamate have been implicated in 
neuroplastic changes that alter brain circuitry to seek after abused substances rather than functional 
behavior in response to stressors.4 
There are two main medical treatment approaches to opioid addiction: direct supervised 
detoxification and opioid-substitution treatment. Although complete abstinence from opioid use is ideal, 
relapse rates are high and therefore long-term substitution is the mainstay of treatment. The main 
objective of treatment is to prevent illicit opioid use and injection behavior and to minimize concomitant 
risks such as hepatitis C infection and HIV. In young patients with a short history of oral opioid 
dependence and a strong support system, complete abstinence is probable and more aggressive treatment 
approaches can be initiated. 5  
Detoxification can be achieved through the use buprenorphine/naloxone. Buprenorphine, 
originally developed as an analgesic, is a synthetic form of the opioid thebaine, which functions as a 
partial mu-receptor agonist and kappa- receptor antagonist. It binds to mu-receptors with a higher affinity 
than endogenous opioids and illicit opioids such as heroin, which are full-mu agonists. Therefore, binding 
of buprenorphine will precipitate withdrawal symptoms in intoxicated individuals as a partial-mu receptor 
agonist displaces a full-mu receptor agonist. However, since buprenorphine is a partial mu-receptor 
agonist, it produces a mild euphoric and sedation effect, which can minimize withdrawal symptoms 
compared to a full mu-receptor antagonists.6 Naloxone, a mu-receptor antagonist, binds with a high 
affinity to mu-receptors and blocks the activation of these receptors. Naloxone has a poor bioavailability 
when given orally but if injected, precipitates withdrawal symptoms, thus discouraging the improper use 
of the medication.4 
Patients are usually started on 2-4 mg of buprenorphine/naloxone within 6-24 hours of the last 
opioid dose. Withdrawal symptoms, commonly described as flu-like symptoms, including nausea, 
vomiting, diaphoresis, yawning, fatigue, myalgia, diarrhea and mydriasis occur within 36-72 hours of 
drug-cessation. Drug cravings tend to occur sooner, within 4-6 hours after the last opioid dose. It is 
critical that treatment begin within this timeframe to reduce withdrawal symptoms and increase the 
probability of patient compliance.7 If treatment is started too soon, buprenorphine will exhibit a 
withdrawal effect as it displaces the full-agonist of the abused opioid. Delaying treatment increases the 
risk of illicit drug use in order to minimize the negative symptoms of drug withdrawal.  
Stabilization and maintenance is achieved once the patient no longer has withdrawal symptoms or 
cravings. Both buprenorphine/naloxone and methadone have proven to be effective in maintenance 
treatment. Methadone was developed in 1964 as a response to the post-WWII heroin epidemic in New 
York City.8 It functions as a complete mu-agonist and is prescribed in legally certified clinics in which 
daily appointments are required for drug administration. Patients are usually maintained on a dose of 80-
120mg QD. Since methadone is a complete mu-agonist, there is no ceiling-effect, which allows for the 
potential of abuse, overdose and mortality as a result of respiratory depression. This led to the utilization 
of buprenorphine and subsequently buprenorphine/naloxone as a more convenient and safe approach to 
opioid dependence. It has been shown that higher maintenance doses of buprenorphine (8-16mg) are more 
efficacious in retention rates compared to lower doses (1-4 mg).9 Although, doses should be 
individualized such that the most minimal dose is prescribed that prevents withdrawal, cravings and illicit 
opioid use. This can often take several months of weekly increment adjustments.10  
Several studies have been conducted on the effectiveness of both methadone and buprenorphine 
but there is limited information on the use of buprenorphine/naloxone. This study aims to investigate the 
effectiveness of buprenorphine/naloxone compared to methadone in treatment retention and effectiveness 
among opioid dependent individuals.  
 
PICO 
Population: Opioid dependent individuals 
Intervention: Methadone 
Comparison: Buprenorphine-naloxone 
Outcome: Improved retention rates and efficacy in treatment programs 
  
CLINICAL QUESTION 
Among opioid dependent individuals does methadone as compared to buprenorphine-naloxone improve 
retention rates and efficacy in treatment programs? 
 
METHODS 
An initial literature search of PubMed 
using the search terms “methadone” and 
“buprenorphine-naloxone” and “opioid 
dependence” yielded 14 results. 
Inclusion criteria included randomized 
control trials and meta-analyses with 
publication dates within the last 5 years. 
A further literature search of Scopus 
using the search term “buprenorphine-
naloxone versus methadone” yielded 25 
results. Duplicate articles were removed 
resulting in a total of 36 results. These 
studies were initially excluded based on 
relevance to the research study aim. For 
example, some studies examined the 
characteristics of opioid dependent 
individuals or the abuse potential of 
these maintenance drugs. Once 26 
irrelevant studies were excluded the 
remaining studies were assessed and 
excluded based on treatment outcomes. 
For example, studies with detoxification 
or quality of life improvement as 
outcomes were removed and only those that measured treatment retention and efficacy were included. A 
total of three articles were selected to be included in this analysis.  
 
 
 
 
 
RESULTS 
 
Study 1  
Methadone and Buprenorphine-Naloxone are Effective in Reducing Illicit Buprenorphine and Other 
Opioid Use, and Reducing HIV Risk Behavior-Outcomes of a Randomized Trial. Otiashvili et al. 11 
  
Objective: to determine treatment retention with buprenorphine-naloxone or methadone in buprenorphine 
injection users and the impact of these treatments on substance use and HIV prevalence in the Republic of 
Georgia. 
  
Study Design: the study was conducted at the Addiction Research Center of Alternative Georgia, which 
is a non-profit research institute affiliated with the Center for Medical, Socio-economic and Cultural 
issues, an addiction program that provides in-patient detoxification, psychosocial outpatient treatment and 
methadone maintenance. 
 
Table 1. Inclusion and exclusion criteria for study participation. ICD-10=10th revision of the 
International Statistical Classification of Diseases and Related Health Problems. 
Inclusion Criteria Exclusion Criteria 
Opioid dependence with physiologic 
features based on the ICD-10 for the past 3 
or more years 
 
Buprenorphine injection ≥10 times within 
the past 30 days. 
 
Opioid positive urine test 
 
Stable address within the Tbilisi area 
Under the age of 25 
 
On methadone maintenance in the last 4 
weeks 
 
No home or cellular number at which the 
patient could be reached 
 
Unwillingness or inability to give informed 
consent 
          
Patients were recruited through various methods, which included fliers, word-of-mouth and 
advertisements and further selected based on several criteria (table 1).  Selected patients were stratified 
based on gender and age then randomized 1:1 to methadone or buprenorphine-naloxone treatment groups 
through the Statistical Computer Program R version 2.6.2, which synthesizes a random allocation 
sequence. 
          
Methadone and buprenorphine-naloxone were administered under direct supervision 7 days a week. 
Before treatment introduction, an initial assessment was conducted. Baseline assessments were then 
obtained weekly for 12 weeks then at week 20, whereas comprehensive assessments were gathered at 
weeks 4, 8, 12 and 20 (table 2.). Opioid craving was assessed by an opioid-specific visual analogue scale. 
The urine drug screen screened for the following: opioids, benzodiazepines, amphetamines, 
buprenorphine, methadone and Tetrahydrocannabinol (THC). 
  
Table 2.  Tests performed at each assessment. The urine drug screen tested for opioids, 
benzodiazepines, amphetamines, buprenorphine, methadone and THC. ASI= Addiction 
Severity Index, 5th edition, TLFB=a timeline follow-back for self-reported drug use, 
RAB=Risk Assessment Battery, a self-reported measure of drug and sexual HIV risk 
behaviors. 
Initial Assessment Baseline Assessment Comprehensive Assessment 
Physical Exam Urine drug screen ASI 
CBC Opioid craving RAB 
Glucose TLFB   
Bilirubin     
AST/ALT     
HIV and Hepatitis 
B/C testing 
    
Urine drug screen     
 
Study Results: A total of 80 patients were assessed between January 25 and September 27, 2011.  All 
participants were Caucasian, 4 of which were female with an average age of 34 years. The mean years of 
opioid injection use was 5.8. The main drugs injected among participants were heroin, buprenorphine, 
opium, desomorphine and amphetamines. 
  
The number of urine samples tested positive for opioids was significantly different between the two 
treatment groups (p=0.03). Although there is a significant difference between the treatment groups in the 
number of opioid-positive urine screens, the overall quantity was low in both groups. Only 1.5% of 
samples in the methadone treatment group and 0.2% in the buprenorphine-naloxone group tested positive.   
  
Injection risk behavior, which included needle, cooker, cotton and syringe sharing, was significantly 
reduced among both treatment groups with no significant difference between buprenorphine-naloxone 
and methadone (p=0.1). Only 10% and 23% of total risk assessment battery (RAB) reports indicated 
injection risk behavior in buprenorphine-naloxone and methadone treatment groups respectively. 
  
At the 20 week follow-up, 66 participants were evaluated, of which, 37 participants were still on 
maintenance therapy with 34 on methadone and 3 on buprenorphine-naloxone. Significantly fewer 
patients were using opioids illicitly in those being treated (5.6%) compared to those no longer on 
maintenance treatment (27.6%, p<0.001). 
  
 Study Critique: Strengths include daily observed dosing and therefore ensured compliance and limited 
loss to follow-up during the initial 12-week study (85% of participants completed the study, 5 participants 
in the Suboxone (Buprenorphine/naloxone) and 7 in the methadone study left) with the intention to 
treatment method utilized for those lost to follow-up. 
  
There were several limitations to this study. The study duration was short being only 12-weeks long, 
which may not sufficiently determine the efficacy of drug maintenance therapy. The sample population 
was nearly exclusively male with only 4 female participants, which limits the application of this study to 
females in the general population. The lack of follow-up at 20 weeks was also a substantial limitation. 
Only 3 participants were using Suboxone as maintenance therapy at 20 weeks. Furthermore, the reasons 
for the lack of Suboxone use were not addressed.  The authors also claimed that both medications 
significantly reduced opioid cravings but no data was reported to verify such a statement.  
 
Study 2 
Buprenorphine-Naloxone Versus Methadone Maintenance Therapy: A Randomized Double-Blind Trial 
With Opioid-Dependent Patients. Kamien et al. 12 
  
Objective: to compare buprenorphine-naloxone with methadone for maintenance treatment of opioid 
dependence. 
  
Study Design: this study took place at a licensed, outpatient opioid-treatment facility for adults in 
Denver, Colorado, called the Vine Street Center. This facility offered a range of pharmacotherapies for 
the treatment of opioid dependence along with comprehensive counseling services. 
Table 3. Inclusion and exclusion criteria for study participation. 
Inclusion Criteria Exclusion Criteria 
At least 18 years of age 
 
In good health 
 
Met Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition criteria for 
opioid dependence 
 
Met Food and Drug Administration criteria 
for methadone maintenance treatment 
 
Using heroin or prescription opioids or 
receiving methadone maintenance 
treatment 
Evidence of active psychosis, manic-
depressive illness, organic psychiatric 
disorders or serious medical illnesses 
 
 
 
          
Patients were recruited through newspaper and poster advertisements as well as referred from local 
treatment programs. They were then selected based on inclusion and exclusion criteria (Table 3). Patients 
were not excluded from the study for having codependence on other drugs. Participants received a full 
explanation of the procedures of the study and were then provided written informed consent before being 
enrolled into the study. After enrollment they completed a comprehensive intake interview to determine 
study eligibility.  
 
The study was a 17-week, double-blind, double-dummy, randomized clinical trial that compared 4 study 
groups: 8 mg buprenorphine-2 mg naloxone, 16 mg buprenorphine-4 mg naloxone, 45 mg methadone and 
90 mg methadone. Double-dummy is a technique used to keep the study blinded when the two treatments 
can not be made identical, in this case one medication was a liquid and the other a tablet, so both groups 
received a liquid and a tablet, one of which was the placebo. Minimum likelihood allocation, a method of 
assigning participants to different groups while taking into account continuous and discrete factors 
simultaneously, was used to randomly assign the participants sequentially to 1 of the 4 groups while 
controlling for gender, methadone and/or Vine Street Center treatment history, and duration of regular 
opioid use (< or >15 years).  
 
Participants were required to attend the clinic daily for medication. All participants, regardless of the 
group they were assigned, received an oral solution first, followed by the tablets to meet the double-blind 
and double-dummy requirements. The nurse provided patients with either methadone or placebo solution 
to drink and then a buprenorphine-naloxone tablet or placebo tablet in a plastic cup. 
 
Urine samples were collected 3 times a week under observation before medications were administered 
and analyzed on site for the presence of opioids. They were also collected on a randomly chosen day each 
week in the same manner. Breath alcohol samples were collected on urine testing days as part of routine 
clinical procedure, as participants were not allowed to attend clinic intoxicated. 
 
Each participant received 1-hour of individualized, manualized behavioral counseling with a trained 
therapist every other week throughout the study. These sessions focused on lifestyle changes and also 
incorporated AIDS education. 
 
If participants failed to obtain their medications on 3 consecutive days or if they did not provide urine 
samples on 5 consecutive days where it was required then they were withdrawn from the study and 
offered alternative treatment at the center or referral to other treatment facilities. Those who fell into this 
category were offered a compassionate extension of treatment where they could continue to blindly 
receive treatment for the remainder of the study but they were not included in the study results any longer. 
 
The primary outcome measure in this study was the amount of opioid abstinence achieved over time. 
Missed urine samples were considered positive for analysis purposes. Medication compliance was 
measured by the number of medication doses ingested by each participant. Retention time was measured 
by the percent of patients active in the study over time and was calculated from the day of the first dose to 
the day of the last dose.  
 
Statistical analysis was performed using analysis of variance (ANOVA) or chi-square tests. ANOVA is a 
collection of statistical models used to determine differences among and between treatment groups. A 
Chi-square test is a statistical means of comparing the fit between observed and theoretically expected 
values. Hierarchical linear modeling (HLM), an ordinary least square regression-based analysis taking the 
hierarchical structure of data into account,  was used to examine opioid abstinence and use of non-opioid 
drugs over time. The Kaplan-Meier statistic was used with 95% confidence intervals to estimate retention 
time. Significant differences between the different groups were determined using Log rank chi-square 
tests. 
 
Study Results: a total of 268 participants were chosen to participate in the study and were randomly 
assigned to the 4 study groups. A malfunction of the minimum-likelihood allocation computer software 
resulted in uneven numbers being assigned to the groups, but they did not differ based on gender, 
ethnicity, age, years opioid use, previous history of methadone treatment, or history of treatment at the 
Vine Street Center.  
 
The percentage of urine samples that were opioid-free over time among drug groups and drug doses did 
not differ significantly. In general, participants increased their percentage of opioid-negative urine 
samples over the course of the study and was not predicted by either drug type or dose. Results from the 
homogeneity of proportions test found the percent of participants with at least 12 consecutive opioid-
negative urine samples differed by dose but not by drug. Those receiving higher doses of either 
buprenorphine-naloxone or methadone were more likely to have at least 12 consecutive opioid-negative 
urine samples as compared to those receiving the lower doses. 
 
ANOVAs were conducted to determine if the treatment groups differed in the amount of medication 
ingested and demonstrated no significant difference in medication compliance based on drug or dose.  
 
The most commonly used drugs other than opioids among study participants were cocaine and 
cannabinoids. HLM models showed that nonopioid drug use did not change significantly over time or 
across the different study groups. 
 
Kaplan-Meier survival analyses and log rank chi-square tests were used to estimate retention time and 
found no significant different based on the drug used. 
 
Ninety percent of participants who completed the study elected to continue treatment under the 
compassionate extension of treatment program and there were similar percentages of participants in each 
treatment group who decided to continue treatment. Medication and dose received during the study did 
not significantly affect the duration of time that participants chose to receive treatment after the end of the 
study. 
  
Study Critique: the strengths of this study included conservative analytical procedures (ex: all missing 
urine samples were considered positive), a rapid buprenorphine dose induction procedure and therapeutic 
maintenance dose of each study medication used, the study being conducted at a licensed, community-
based opioid treatment center and exposing patients to buprenorphine-naloxone for longer time periods 
than previous studies. 
 
Limitations of this study included the uneven number the participants assigned to the 4 treatment groups 
and the steadily decreasing numbers of patients due to study dropout leading to loss to follow-up. There 
was also the potential that participants could tell which tablet or solution was placebo even though they 
tried to control for this. 
 
Study 3 
Treatment Retention among Patients Randomized to Buprenorphine/Naloxone Compared to Methadone 
in A Multi-site Trial. Hser et al. 13 
 
Objective: to examine patient and medication characteristics associated with retention and continued 
illicit opioid use in methadone versus buprenorphine-naloxone treatment. 
  
Study Design: this was a secondary analysis of an original study that was a multisite, open-label, phase 
IV study to assess liver function in participants randomized to receive either methadone or 
buprenorphine-naloxone. The study took place at 9 federally licensed opioid treatment programs across 
the United States. Participants were used from the original study. There were 1,269 eligible participants. 
Two women were excluded from the study since they became pregnant and required medication 
reassignment This lead to the 1,267 participants that were actually included in this study. The higher 
dropout rate seen in the buprenorphine-naloxone group resulted in an uneven number of study participants 
in the two groups.  
 
Participants  had to go to the clinic daily for observed medication administration excluding Sundays, 
holidays, and when take-home medications were deemed appropriate by Federal/State law. The study was 
conducted over a 24-week period and then tapered over of <8 weeks or referred for continued treatment 
with study completion at 32 weeks.  
 
Assessments were conducted on a weekly basis including urine drug screens and adverse event 
assessments. Self-reported drug use data were collected every four weeks. Participants who missed 14 or 
more consecutive days of the medication were withdrawn from the study.  
 
Treatment completion was defined as a participant continuing the assigned medication for 24 weeks 
without being withdrawn from the study. Treatment retention was calculated based on the number of days 
in treatment since randomization until the last day the medication was taken. 
 
Chi-square tests or t-tests were used to determine statistically significant differences between the two 
study groups. The Kaplan Meier method and log rank tests were used to assess the unadjusted survival 
function. Cox proportional hazard models, used in survival analysis to assess the importance of different 
covariates in the survival times of individuals through the hazard function,  were performed to compare 
survival rates between the two groups. The generalized estimating equations approach, used to estimate a 
possible unknown correlation between outcomes, was used to find the relationship between dose and 
opioid use over time. 
 
Study Results: This study found that days of opioid use in the past 30 days did not significantly differ 
between the group taking buprenorphine-naloxone and methadone. 
 
This study showed that significantly fewer participants in the buprenorphine-naloxone group completed 
the 24 week treatment compared to those in the methadone group. This was due to significantly more 
participants in the buprenorphine-naloxone group dropping out of the study within the first 30 days than 
in the methadone group. Even among those who stayed in the study more than 30 days, the 
buprenorphine-naloxone group still showed a significantly lower completion rate than the methadone 
group. It was also found that more buprenorphine-naloxone participants than methadone participants 
dropped out because they no longer wished to participate in their assigned treatment regimen. 
 
Doses of methadone greater than 60 mg demonstrated 80% or better retention with 120 mg or higher 
showing a 91% completion rate. Buprenorphine-naloxone, on the other hand, showed a linear relationship 
between dose and retention rate with increasing doses yielding better retention rates. The highest dose in 
this category was 30-32 mg resulting in a completion rate of approximately 60%.  
 
For the urine analysis, increased dose was found to be negatively related to continued opiate use. 
Buprenorphine-naloxone participants had lower likelihood of positive opiate test results for every mg 
dose increase compared to those in the methadone group. Additionally, opiate use was significantly lower 
in the buprenorphine-naloxone group than the methadone group during the first 9 weeks of treatment. 
 
The Cox model was used to identify additional measures to help predict retention rates. It was found that 
younger age, Hispanic populations, and use of opioids, amphetamine, cannabinoids or cocaine were 
associated with dropout from the study and shorter retention rates. Location (programs on the west coast) 
and higher dose of medication were associated with lower risk for dropping out of the study. It was also 
found that gender affected the two study groups opposite one another. In other words, males in the 
buprenorphine-naloxone group were less likely to drop out while males in the methadone group were 
more likely to drop out. 
  
Study Critique: the strengths of this study included being the first large scale randomized trial to 
compare treatment retention of participants on buprenorphine-naloxone and methadone, being conducted 
in community treatment programs in the United States, revealing additional findings regarding 
buprenorphine-naloxone dose and treatment retention, and identifying additional participant 
characteristics predicting dropout (age, ethnicity, other drug use, etc.). 
 
Limitations of this study included limited measures of participant motivation as well as program and 
community characteristics that are likely to influence treatment retention, such as location of treatment 
centers and years of regular opioid use. Other limitations that should be noted are that it was an open-
label and unblinded clinical trial. 
 
DISCUSSION 
 
Complete abstinence from opioid use is the ideal objective in the treatment of opioid dependence but is 
improbable with exceedingly high relapse rates. For example, one study, which followed opioid-
dependent individuals 30 days after a 3-day inpatient medically supervised opioid withdrawal program, 
discovered that only 17% had remained abstinent.14 Therefore, treatment efforts are directed at preventing 
illicit use and its subsequent consequences such as impaired social functioning and disease risk. 
Examining treatment retention rates and absence from use of illicit opioids are therefore cornerstones in 
assessing the effectiveness of maintenance treatment. 
  
Hser et al. (2014) demonstrated that treatment retention was significantly higher in those treated with 
methadone compared to buprenorphine-naloxone (p<0.01). Of those treated with methadone, 74.1% 
remained in treatment at 24 weeks compared to 46.1% of those treated with buprenorphine-naloxone. 
Conversely, Otiashvilis et al. (2013) showed no difference in retention rates at 12-weeks but higher 
retention rates among those on methadone (92.5%) than those on buprenorphine-naloxone (7%) at 20 
weeks. This large discrepancy seen between the drugs is consistent with numerous other studies and could 
be the result of multiple factors.9,15 It has been postulated that poorer retention rates for buprenorphine are 
due to the fact that it functions as a partial mu-receptor agonist and therefore does not have the full opioid 
effect and is less satisfying to patients. Another possibility is that it is easier to withdraw from 
buprenorphine, as withdrawal symptoms are substantially milder than those seen with methadone. Others 
have speculated that buprenorphine retention is inferior to methadone because buprenorphine can induce 
withdrawal symptoms upon initiation by displacing heroin, a full agonist.9 This is less convincing since 
retention rates of buprenorphine-naloxone were shown to be the same as methadone at 12 weeks in the 
Otiashvilis study and higher in the Kaimen et al. study (35 vs. 33 participants). Another consideration is 
that research values of buprenorphine-naloxone retention rates may not accurately reflect in-practice 
retention rates. In order to ensure research accuracy, research subjects must take the drug in-clinic.  This 
retracts from the potential benefit of taking buprenorphine-naloxone at home, which may actually 
increase patient compliance and retention rates. 
  
Buprenorphine-naloxone was superior to methadone in treatment efficacy. Illicit opioid use was 
significantly lower among the buprenorphine-naloxone group within the first 9 weeks of treatment 
compared to methadone (p<0.01). Similarly, there were significantly more opioid-positive urine samples 
in the methadone group than the buprenorphine-naloxone group (p=0.03). Albeit, all three studies 
indicated that both buprenorphine-naloxone and methadone were effective at decreasing illicit opioid use. 
Use of concomitant opioids may be lower with buprenorphine-naloxone treatment as a result of the 
“ceiling effect”. Higher doses of buprenorphine-naloxone saturate mu-receptors without an additional 
euphoric effect and prevent euphoria from the supplementation of another opioid.  In contrast, higher 
doses of methadone or the addition of another opioid will lead to a greater euphoric effect, preventing the 
discouragement of illicit opioid use. 
  
These studies gleamed further insight on dosing regimens. Increased dosage was associated with both 
higher retention rates and less likelihood of illicit opioid use. Kamien et al. (2008) showed a higher 
retention rate among those on high dose (16mg) buprenorphine-naloxone (12.5 weeks) than low dose 
(8mg) buprenorphine-naloxone (12.1 weeks) although, retention rates were lower among high dose 
(90mg) methadone (12.2 weeks) compared to low dose (45mg, 13.2 weeks). The reason for poorer 
retention rates among the high dose methadone treatment group remains unclear and is inconsistent with 
findings from Hser et al. (2014), which showed higher retention rates with higher doses for both treatment 
groups. Furthermore, higher doses were associated with fewer positive urine samples in both studies. 
These findings are consistent with other studies and may suggest that dosage is more important than the 
drug used. A meta-analysis conducted by Barnett et al. (2001) slightly favored methadone in treatment 
retention but dosing had the most substantial impact on outcomes. Patients on 60mg of methadone were 5 
times more likely to withdraw from treatment than those on 80mg. Additionally, an 8-12mg dose of 
buprenorphine was more effective than 60mg of methadone, although, 80mg of methadone was superior 
to all other treatment modalities. 16 
 
 
CONCLUSION 
 
With an inconsistency in retention rates and somewhat equivocal effectiveness observed between 
buprenorphine-naloxone and methadone, it is essential to take into consideration other influential 
characteristics of these drugs. The benefits of utilizing buprenorphine-naloxone have been examined in 
several studies and include less dependence and tolerance, lower risk for fatal overdose, and 
cardiotoxicity (QT prolongation and torsade des pointes), longer duration of action and fewer withdrawal 
symptoms.9,17,18 Maintenance therapy with buprenorphine-naloxone also demonstrates a substantial 
advantage over methadone in that methadone typically requires daily visits to a licensed opioid treatment 
clinic for supervised administration whereas buprenorphine-naloxone can be dispensed at pharmacies 
with a one-month supply and 6 refills.16 This lessens provider burden and may function to enhance patient 
compliance. Furthermore, buprenorphine-naloxone has markedly less divergence rates than methadone 
and when used illicitly; it is typically only used to combat opioid withdrawal symptoms or reduce the use 
of other opioids.20 This is in large due to a less satisfactory euphoria generated by buprenorphine 
compared to methadone, which is reflected  by its low street value and lack of divergence.20,21 Therefore, 
if methadone is replaced by buprenorphine-naloxone for the treatment of opioid dependence, this may 
substantially reduce the illicit use of prescription opioids. Consequently, we recommended 
buprenorphine-naloxone as a first-line treatment for opioid-dependent individuals.  
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